3 assets in NF2-Related Schwannomatosis

Therapeutic assets addressing NF2-Related Schwannomatosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Benzenesulfonamide, N-Methyl-3-(1-Methyl-1H-Imidazol-4-Yl)-4-[[[4-(Trifluoromethyl)Phenyl]Methyl]Amino]- NF2-Related Schwannomatosis	Ikena Oncology	P1	CC (43)
Osimertinib NF2-Related Schwannomatosis	Ikena Oncology	P1	CC (43)
st002 NF2-Related Schwannomatosis	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	N/A	NR ()